Astrin's New Blood Test Aims to Redefine Early Breast Cancer Detection

SAINT PAUL, Minn. – July 30, 2026 – A newly published study is heralding a potential paradigm shift in breast cancer screening, validating a blood test that demonstrates over 92% accuracy in detecting the disease, even in its earliest stages. The test, named Certitude, comes from cancer intelligence firm Astrin Biosciences and leverages a novel approach that could solve long-standing challenges in diagnosing a cancer that affects millions of women globally.

The landmark research, published in the peer-reviewed journal Breast Cancer: Targets and Therapy, details the performance of Certitude, a liquid biopsy that analyzes proteins in the blood rather than DNA. For investors and industry analysts tracking the journey from prototype to profit, this publication is a critical milestone, moving Astrin's technology from the lab bench toward broad clinical adoption and commercial viability.

A New Signal in a Crowded Field

For decades, the foundation of breast cancer screening has been the mammogram. While it has saved countless lives, its limitations are well-documented, particularly for the nearly 50% of women with dense breast tissue. On a mammogram, dense tissue appears white, the same color as potential tumors, creating a "white-on-white" effect that can mask cancers. This has led to a reliance on supplemental screenings like MRI or ultrasound, which can be costly, inconvenient, and carry a high rate of false positives.

The search for a better solution led to the rise of liquid biopsies—simple blood tests designed to find cancer signals. However, most of these tests have focused on detecting circulating tumor DNA (ctDNA). This approach has proven highly effective for cancers like colorectal, but early-stage breast tumors present a biological hurdle: they shed roughly one-tenth the amount of DNA, making them incredibly difficult to spot with ctDNA tests. As a result, even the most advanced multi-cancer detection panels often show low sensitivity for breast cancer or omit it entirely.

Astrin Biosciences sidestepped this problem by looking for a different signal: proteins. The company's patent-pending proteomic technology doesn't just look for proteins shed by the tumor itself. Instead, it analyzes the complex "crosstalk" between cancer cells and the body's own immune and stromal cells. This communication network creates a distinct protein signature in the blood long before a tumor is large enough to be seen on an image. By using advanced mass spectrometry to create a deep profile of over 9,000 proteins and applying proprietary machine learning algorithms, Certitude can identify these faint, early signals of disease.

From the Lab to the Clinic: Validating 'Certitude'

The journey from an innovative concept to a commercially viable diagnostic hinges on rigorous scientific validation. The publication of its study provides just that. In the validation cohort of 397 women, the Certitude test achieved a sensitivity of 92.6% (the ability to correctly identify those with the disease) and a specificity of 92.3% (the ability to correctly identify those without it).

Perhaps more importantly for a screening tool, the test demonstrated a negative predictive value (NPV) of 99.87%. In practical terms, this means that a negative result provides extremely high confidence that breast cancer is not present, potentially preventing unnecessary and stressful follow-up procedures. The test’s accuracy held firm across all cancer stages (0-IV) and various subtypes, including the notoriously difficult-to-detect Invasive Lobular Carcinoma (ILC).

"Our proteomic assay demonstrates high sensitivity and specificity in women with breast cancer, especially at early stages," said Justin Drake, Ph.D., Chief Science Officer at Astrin Biosciences and the study's corresponding author. "By reducing false positives more than 10-fold compared to MRIs or contrast enhanced mammograms, Certitude represents a promising path forward as a supplemental screening option that is convenient and accessible."

Addressing a Critical Unmet Need

The most immediate impact of Certitude could be for women who fall into diagnostic gray areas. The test is intended as a supplemental tool for several key groups: women over 40 with dense breasts and a negative mammogram; patients with inconclusive mammographic findings (BI-RADS 0 or 3); and high-risk patients needing additional screening.

For women with dense breasts, the test offers newfound clarity. The study showed that Certitude detected 93% of breast cancers in a simulated population of women with dense tissue, many of which could have been missed by mammography alone. By providing a clear, blood-based risk assessment, the test can help guide decisions about whether further imaging is truly necessary, reducing both patient anxiety and healthcare costs associated with false alarms.

This sentiment was echoed by a leading expert in the field. "Breast cancer screening has relied on the same imaging techniques for decades. The research published today represents a real step forward for women, showing that a proteomic-based blood test can detect earliest signals of breast cancer with high confidence," said Dr. Pooja Advani, Medical Oncologist and Director of the Multidisciplinary Breast Clinic at Mayo Clinic, who also serves on Astrin's Scientific Advisory Board.

The Path to Market: Navigating Regulation and Reimbursement

With scientific validation in hand, Astrin Biosciences is now navigating the complex path to commercialization. The company, which has raised $22.9 million in funding, is launching Certitude as a Laboratory Developed Test (LDT). This regulatory pathway allows CLIA-certified and CAP-accredited labs like Astrin's to offer their own validated tests without undergoing the lengthy FDA approval process, enabling a faster route to market.

The test became available by prescription in select U.S. markets in early 2026. The company is pursuing a phased rollout, partnering with established healthcare providers to ensure a seamless clinical workflow, especially for patients who receive a positive result and require follow-up. The lab has already validated a high-throughput pipeline capable of processing hundreds of samples weekly, a key capability for scaling operations.

However, widespread adoption will ultimately depend on cost and insurance coverage. Astrin has introduced an "Early Access" program for tests reserved by the end of 2026, with an anticipated future list price of $750 or more. The next major hurdle for the company will be securing reimbursement from Medicare and private payers, a critical step to making the test an accessible part of the standard of care. As a supplemental tool, Certitude doesn't aim to replace mammography but to make the entire screening process smarter, more personalized, and far more precise for millions of women.